Cetuximab Based Chemotherapy in Recurrent and Metastatic SCC of Esophagus – A Real World Short Case Series from a Tertiary Cancer Care Center
Fuente:
Zenodo
Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | English |
| Published: |
Zenodo
2025
|
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901932659965952 |
|---|---|
| author | Dr Siddhesh Rajendra Tryambake |
| author_facet | Dr Siddhesh Rajendra Tryambake |
| contents | <p><strong><em><span>Abstract</span></em></strong></p> <p><strong><em><span>Background: </span></em></strong><em><span>A significant fraction of esophageal cancers has an increased amount of the epidermal growth factor receptor (EGFR). Prior studies have examined tyrosine kinase inhibitors that target EGFR, but there is currently a lack of information regarding the effects of EGFR-directed monoclonal antibody therapy in these specific cancer types. A retrospective audit was carried out at a single institution, specifically targeting patients who were diagnosed with unresectable or metastatic esophageal squamous cell carcinoma and received cetuximab-based treatment. <strong>Patients and Methods: </strong>15 patients who previously had treatment for recurrent or metastatic esophageal squamous cell carcinoma (SCC) were included in the study and retrospectively analyzed. These patients were treated with cetuximab, a monoclonal antibody, based therapy, on a weekly basis. The treatment started with an initial dose of 400 mg/m2, followed by weekly infusions at a dose of 250 mg/m2. Some patients had received cetuximab as a single agent while others received the same with concurrent chemotherapy. Patients were monitored for adverse effects, therapy efficacy, and overall survival.</span></em></p> <p><strong><em><span>Results: </span></em></strong><em><span>A total of 15 patients (median age of 67 years at the time of analysis) were evaluated. 8th edition AJCC staging system revealed 9 (60%) patients to be having metastatic disease, 5 33.33%) recurrent stage and 1 patient having unresectable disease. The Eastern Cooperative Oncology Group (ECOG) performance score (PS) was I in 4 (26.7%) and II in 11 (73.3%). Majority of patients were males (73.3%) with only 1 patient having multiple comorbidities and the rest having single or none. 5 patients (33.33%) received cetuximab as a single agent, 3 with methotrexate and nab-paclitaxel each, while 2 patients received cetuximab with paclitaxel and paclitaxel plus carboplatin combination each. 9 patients (60%) had received cetuximab or cetuximab based chemotherapy in 1st and 2nd line, while the rest received the same in 3rd and above lines. Median OS was 34 months and 2-year OS rate in the study was 80% while median PFS was 3 months and 6-month PFS rate was 7 % only. 1 patient had complete response; 5 patients (33.33%) had partial response; 9 patients (60%) had disease progression on initial assessment. overall response rate (ORR) as well as disease control rate (DCR) was 40 % at first follow-up as there were no patients with stable disease. </span></em></p> <p><strong><em><span>Conclusion</span></em></strong><em><span>: Although well tolerated, cetuximab administered as a single agent had minimal<span> </span>clinical activity in patients with metastatic esophageal SCC. Ongoing<span> </span>studies<span> </span>of<span> </span>EGFR<span> </span>inhibitors<span> </span>in<span> </span>combination<span> </span>with<span> </span>other<span> </span>agents<span> </span>may<span> </span>define<span> </span>a<span> </span>role<span> </span>for<span> </span>these<span> </span>agents<span> </span>in<span> </span>the<span> </span>treatment<span> </span>of<span> </span>esophageal<span>.</span></span></em></p> <p><strong><em><span>Key<span> </span>words</span></em></strong><em><span>:<span> </span>cetuximab,<span> </span>chemotherapy,<span> </span>advanced<span> </span>esophageal<span> </span>cancer,<span> </span>squamous<span> </span>cell<span> </span>carcinoma</span></em></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_14903662 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Cetuximab Based Chemotherapy in Recurrent and Metastatic SCC of Esophagus – A Real World Short Case Series from a Tertiary Cancer Care Center Dr Siddhesh Rajendra Tryambake <p><strong><em><span>Abstract</span></em></strong></p> <p><strong><em><span>Background: </span></em></strong><em><span>A significant fraction of esophageal cancers has an increased amount of the epidermal growth factor receptor (EGFR). Prior studies have examined tyrosine kinase inhibitors that target EGFR, but there is currently a lack of information regarding the effects of EGFR-directed monoclonal antibody therapy in these specific cancer types. A retrospective audit was carried out at a single institution, specifically targeting patients who were diagnosed with unresectable or metastatic esophageal squamous cell carcinoma and received cetuximab-based treatment. <strong>Patients and Methods: </strong>15 patients who previously had treatment for recurrent or metastatic esophageal squamous cell carcinoma (SCC) were included in the study and retrospectively analyzed. These patients were treated with cetuximab, a monoclonal antibody, based therapy, on a weekly basis. The treatment started with an initial dose of 400 mg/m2, followed by weekly infusions at a dose of 250 mg/m2. Some patients had received cetuximab as a single agent while others received the same with concurrent chemotherapy. Patients were monitored for adverse effects, therapy efficacy, and overall survival.</span></em></p> <p><strong><em><span>Results: </span></em></strong><em><span>A total of 15 patients (median age of 67 years at the time of analysis) were evaluated. 8th edition AJCC staging system revealed 9 (60%) patients to be having metastatic disease, 5 33.33%) recurrent stage and 1 patient having unresectable disease. The Eastern Cooperative Oncology Group (ECOG) performance score (PS) was I in 4 (26.7%) and II in 11 (73.3%). Majority of patients were males (73.3%) with only 1 patient having multiple comorbidities and the rest having single or none. 5 patients (33.33%) received cetuximab as a single agent, 3 with methotrexate and nab-paclitaxel each, while 2 patients received cetuximab with paclitaxel and paclitaxel plus carboplatin combination each. 9 patients (60%) had received cetuximab or cetuximab based chemotherapy in 1st and 2nd line, while the rest received the same in 3rd and above lines. Median OS was 34 months and 2-year OS rate in the study was 80% while median PFS was 3 months and 6-month PFS rate was 7 % only. 1 patient had complete response; 5 patients (33.33%) had partial response; 9 patients (60%) had disease progression on initial assessment. overall response rate (ORR) as well as disease control rate (DCR) was 40 % at first follow-up as there were no patients with stable disease. </span></em></p> <p><strong><em><span>Conclusion</span></em></strong><em><span>: Although well tolerated, cetuximab administered as a single agent had minimal<span> </span>clinical activity in patients with metastatic esophageal SCC. Ongoing<span> </span>studies<span> </span>of<span> </span>EGFR<span> </span>inhibitors<span> </span>in<span> </span>combination<span> </span>with<span> </span>other<span> </span>agents<span> </span>may<span> </span>define<span> </span>a<span> </span>role<span> </span>for<span> </span>these<span> </span>agents<span> </span>in<span> </span>the<span> </span>treatment<span> </span>of<span> </span>esophageal<span>.</span></span></em></p> <p><strong><em><span>Key<span> </span>words</span></em></strong><em><span>:<span> </span>cetuximab,<span> </span>chemotherapy,<span> </span>advanced<span> </span>esophageal<span> </span>cancer,<span> </span>squamous<span> </span>cell<span> </span>carcinoma</span></em></p> |
| title | Cetuximab Based Chemotherapy in Recurrent and Metastatic SCC of Esophagus – A Real World Short Case Series from a Tertiary Cancer Care Center |
| url | https://doi.org/10.5281/zenodo.14903662 |